Skip to main content
Top
Published in: BMC Psychiatry 1/2020

Open Access 01-12-2020 | Schizophrenia | Research article

Symptomatic remission affects employment outcomes in schizophrenia patients

Authors: San-Ping Wang, Jung-Der Wang, Jer-Hao Chang, Bo-Jian Wu, Tso-Jen Wang, Hsiao-Ju Sun

Published in: BMC Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

Remission criteria were proposed by Andreasen et al. for classifying patients with schizophrenia according to the severity of psychopathology. Up to the present time, there have been no cohort studies exploring the association between remission status and employment outcomes in patients with schizophrenia. The study explored whether symptomatic remission is significantly associated with employment outcomes in a two-year longitudinal study.

Methods

All 525 stable patients with schizophrenia in the therapeutic community of a public mental hospital in Taiwan were recruited between 2013 and 2015. Employment outcomes, defined as the cumulative on-the-job duration (months/per year) and income (new Taiwan dollars, NT$/per year), were investigated at the end of 1- and 2-year follow-up periods after enrollment. For repeated measurements, linear mixed models were constructed to examine the association between symptomatic remission and employment outcomes after controlling for potential confounding variables including age, sex, education, type and daily dose of antipsychotics, cognitive function, psychosocial functioning and initial employment type.

Results

The average age of patients was 51.8 years, and 65.3% were males. Among them, 124 patients (23.6%, 124/525) met the remission criteria at baseline. The linear mixed-model analysis showed that patients who had symptomatic remission were employed 0.8 of a month longer (p = 0.029) and earned NT$3250 more (p = 0.001) within 1 year than those who did not show symptomatic remission.

Conclusion

Our study suggests that assessing symptomatic remission is a useful part of monitoring treatment effectiveness for schizophrenia, and all strategies targeting the bio-psycho-social domains to attain symptomatic remission are paramount to maintaining favorable employment outcomes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Jeste DV. A fulfilling year of APA presidency: from DSM-5 to positive psychiatry. Am J Psychiatry. 2013;170(10):1102–5.PubMed Jeste DV. A fulfilling year of APA presidency: from DSM-5 to positive psychiatry. Am J Psychiatry. 2013;170(10):1102–5.PubMed
3.
go back to reference Jeste DV, Lieberman EJA, Fassler D, Peele R. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. Washington DC: American Psychiatric Association; 2013. Jeste DV, Lieberman EJA, Fassler D, Peele R. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. Washington DC: American Psychiatric Association; 2013.
4.
go back to reference Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505–11.PubMedCrossRef Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505–11.PubMedCrossRef
5.
go back to reference Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119–36.PubMedCrossRef Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119–36.PubMedCrossRef
6.
go back to reference Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull. 2005;31(4):910–21.PubMedCrossRef Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull. 2005;31(4):910–21.PubMedCrossRef
7.
go back to reference Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1–21.PubMedCrossRef Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1–21.PubMedCrossRef
8.
go back to reference Fasseeh A, Nemeth B, Molnar A, Fricke FU, Horvath M, Koczian K, et al. A systematic review of the indirect costs of schizophrenia in Europe. Eur J Public Health. 2018;28(6):1043-9. Fasseeh A, Nemeth B, Molnar A, Fricke FU, Horvath M, Koczian K, et al. A systematic review of the indirect costs of schizophrenia in Europe. Eur J Public Health. 2018;28(6):1043-9.
9.
go back to reference Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
10.
go back to reference Andreasen NC, William T, Carpenter J, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9.PubMedCrossRef Andreasen NC, William T, Carpenter J, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9.PubMedCrossRef
11.
go back to reference Marchesi C, Affaticati A, Monici A, De Panfilis C, Ossola P, Tonna M. Predictors of symptomatic remission in patients with first-episode schizophrenia: a 16years follow-up study. Compr Psychiatry. 2014;55(4):778–84.PubMedCrossRef Marchesi C, Affaticati A, Monici A, De Panfilis C, Ossola P, Tonna M. Predictors of symptomatic remission in patients with first-episode schizophrenia: a 16years follow-up study. Compr Psychiatry. 2014;55(4):778–84.PubMedCrossRef
12.
go back to reference Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113(2–3):210–7.PubMedCrossRef Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113(2–3):210–7.PubMedCrossRef
13.
go back to reference Karow A, Moritz S, Lambert M, Schottle D, Naber D, Initiative E. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry. 2012;27(6):401–5.PubMedCrossRef Karow A, Moritz S, Lambert M, Schottle D, Naber D, Initiative E. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry. 2012;27(6):401–5.PubMedCrossRef
14.
go back to reference Valencia M, Fresan A, Barak Y, Juarez F, Escamilla R, Saracco R. Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome. Neuropsychiatr Dis Treat. 2015;11:2339–48.PubMedPubMedCentralCrossRef Valencia M, Fresan A, Barak Y, Juarez F, Escamilla R, Saracco R. Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome. Neuropsychiatr Dis Treat. 2015;11:2339–48.PubMedPubMedCentralCrossRef
15.
go back to reference Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–9.PubMed Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–9.PubMed
16.
go back to reference Llorca PM, Lancon C, Lancrenon S, Bayle FJ, Caci H, Rouillon F, et al. The "functional remission of general schizophrenia" (FROGS) scale: development and validation of a new questionnaire. Schizophr Res. 2009;113(2–3):218–25.PubMedCrossRef Llorca PM, Lancon C, Lancrenon S, Bayle FJ, Caci H, Rouillon F, et al. The "functional remission of general schizophrenia" (FROGS) scale: development and validation of a new questionnaire. Schizophr Res. 2009;113(2–3):218–25.PubMedCrossRef
17.
go back to reference Lancon C, Bayle FJ, Llorca PM, Rouillon F, Caci H, Lancrenon S, et al. Time-stability of the "functional remission of general schizophrenia" (FROGS) scale. Eur Psychiatry. 2012;27(6):437–41.PubMedCrossRef Lancon C, Bayle FJ, Llorca PM, Rouillon F, Caci H, Lancrenon S, et al. Time-stability of the "functional remission of general schizophrenia" (FROGS) scale. Eur Psychiatry. 2012;27(6):437–41.PubMedCrossRef
18.
go back to reference Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473–9.PubMedCrossRef Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473–9.PubMedCrossRef
19.
go back to reference Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93(1–3):160–8.PubMedCrossRef Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93(1–3):160–8.PubMedCrossRef
20.
go back to reference World Health Organization. International classification of functioning, disability and health: ICF. Geneva: World Health Organization; 2001. World Health Organization. International classification of functioning, disability and health: ICF. Geneva: World Health Organization; 2001.
21.
go back to reference Świtaj P, Anczewska M, Chrostek A, Sabariego C, Cieza A, Bickenbach J, et al. Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. BMC Psychiatry. 2012;12(1):193.PubMedPubMedCentralCrossRef Świtaj P, Anczewska M, Chrostek A, Sabariego C, Cieza A, Bickenbach J, et al. Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. BMC Psychiatry. 2012;12(1):193.PubMedPubMedCentralCrossRef
22.
go back to reference Martini LC, Barbosa JBN, Petreche B, Fonseca AO, Santos FVD, Magalhaes L, et al. Schizophrenia and work: aspects related to job acquisition in a follow-up study. Rev Bras Psiquiatr. 2018;40:35–40.PubMedCrossRef Martini LC, Barbosa JBN, Petreche B, Fonseca AO, Santos FVD, Magalhaes L, et al. Schizophrenia and work: aspects related to job acquisition in a follow-up study. Rev Bras Psiquiatr. 2018;40:35–40.PubMedCrossRef
23.
go back to reference Ucok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011;189(1):33–7.PubMedCrossRef Ucok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011;189(1):33–7.PubMedCrossRef
24.
go back to reference Guo X, Zhang Z, Zhai J, Fang M, Hu M, Wu R, et al. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study. Compr Psychiatry. 2012;53(7):1006–12.PubMedCrossRef Guo X, Zhang Z, Zhai J, Fang M, Hu M, Wu R, et al. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study. Compr Psychiatry. 2012;53(7):1006–12.PubMedCrossRef
25.
go back to reference Keefe RS. Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry. 2007;68(Suppl 14):8–13.PubMed Keefe RS. Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry. 2007;68(Suppl 14):8–13.PubMed
26.
go back to reference Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness. Cochrane Database Syst Rev. 2001;2:CD003080. Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness. Cochrane Database Syst Rev. 2001;2:CD003080.
27.
go back to reference Mohr P, Rodriguez M, Bravermanova A, Melicher T, Ceplova Z, Cermak J, et al. Social and functional capacity of schizophrenia patients: a cross-sectional study. Int J Soc Psychiatry. 2014;60(4):352–8.PubMedCrossRef Mohr P, Rodriguez M, Bravermanova A, Melicher T, Ceplova Z, Cermak J, et al. Social and functional capacity of schizophrenia patients: a cross-sectional study. Int J Soc Psychiatry. 2014;60(4):352–8.PubMedCrossRef
28.
go back to reference Tsang HWH, Leung AY, Chung RCK, Bell M, Cheung W. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry. 2010;44(6):495–504.PubMed Tsang HWH, Leung AY, Chung RCK, Bell M, Cheung W. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry. 2010;44(6):495–504.PubMed
29.
go back to reference Reddy LF, Llerena K, Kern RS. Predictors of employment in schizophrenia: the importance of intrinsic and extrinsic motivation. Schizophr Res. 2016;176(2–3):462–6.PubMedCrossRef Reddy LF, Llerena K, Kern RS. Predictors of employment in schizophrenia: the importance of intrinsic and extrinsic motivation. Schizophr Res. 2016;176(2–3):462–6.PubMedCrossRef
30.
go back to reference Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry. 2012;12:222.PubMedPubMedCentralCrossRef Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry. 2012;12:222.PubMedPubMedCentralCrossRef
31.
go back to reference Carmona VR, Gómez-Benito J, Huedo-Medina TB, Rojo JE, Gómez-Benito J. Employment outcomes for people with schizophrenia spectrum disorder: a meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 2017;30(3):345–66.PubMed Carmona VR, Gómez-Benito J, Huedo-Medina TB, Rojo JE, Gómez-Benito J. Employment outcomes for people with schizophrenia spectrum disorder: a meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 2017;30(3):345–66.PubMed
32.
go back to reference Wu BJ, Lin CH, Tseng HF, Liu WM, Chen WC, Huang LS, et al. Validation of the Taiwanese mandarin version of the personal and social performance scale in a sample of 655 stable schizophrenic patients. Schizophr Res. 2013;146(1–3):34–9.PubMedCrossRef Wu BJ, Lin CH, Tseng HF, Liu WM, Chen WC, Huang LS, et al. Validation of the Taiwanese mandarin version of the personal and social performance scale in a sample of 655 stable schizophrenic patients. Schizophr Res. 2013;146(1–3):34–9.PubMedCrossRef
33.
go back to reference Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389–409.PubMedCrossRef Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389–409.PubMedCrossRef
34.
go back to reference Wu BJ, Lan TH, Hu TM, Lee SM, Liou JY. Validation of a five-factor model of a Chinese mandarin version of the positive and negative syndrome scale (CMV-PANSS) in a sample of 813 schizophrenia patients. Schizophr Res. 2015;169(1–3):489–90.PubMedCrossRef Wu BJ, Lan TH, Hu TM, Lee SM, Liou JY. Validation of a five-factor model of a Chinese mandarin version of the positive and negative syndrome scale (CMV-PANSS) in a sample of 813 schizophrenia patients. Schizophr Res. 2015;169(1–3):489–90.PubMedCrossRef
35.
go back to reference Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13.
36.
go back to reference Guo N-W, Liu H-C, Wong P-F, Liao K-K, Yan S-H, Lin K-P, et al. Chinese version and norms of the mini-mental state examination. J Rehabil Med Assoc. 1988;16:52–9. Guo N-W, Liu H-C, Wong P-F, Liao K-K, Yan S-H, Lin K-P, et al. Chinese version and norms of the mini-mental state examination. J Rehabil Med Assoc. 1988;16:52–9.
37.
go back to reference Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed
38.
go back to reference Brown H, Prescott R. Applied mixed models in medicine. 2nd ed. Hoboken: Wiley; 2006. . Brown H, Prescott R. Applied mixed models in medicine. 2nd ed. Hoboken: Wiley; 2006. .
39.
go back to reference Abdi H. Holm's sequential Bonferroni procedure. Encyclopedia of research design, 1; 2010. Abdi H. Holm's sequential Bonferroni procedure. Encyclopedia of research design, 1; 2010.
40.
go back to reference Burns T, Catty J, Becker T, Drake RE, Fioritti A, Knapp M, et al. The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial. Lancet. 2007;370(9593):1146–52.PubMedCrossRef Burns T, Catty J, Becker T, Drake RE, Fioritti A, Knapp M, et al. The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial. Lancet. 2007;370(9593):1146–52.PubMedCrossRef
41.
go back to reference Bio DS, Gattaz WF. Vocational rehabilitation improves cognition and negative symptoms in schizophrenia. Schizophr Res. 2011;126(1–3):265–9.PubMedCrossRef Bio DS, Gattaz WF. Vocational rehabilitation improves cognition and negative symptoms in schizophrenia. Schizophr Res. 2011;126(1–3):265–9.PubMedCrossRef
42.
go back to reference Dahlan R, Midin M, Shah SA, Nik Jaafar NR, Abdul Rahman FN, Baharudin A, et al. Functional remission and employment among patients with schizophrenia in Malaysia. Compr Psychiatry. 2014;55(Suppl 1):S46–51.PubMedCrossRef Dahlan R, Midin M, Shah SA, Nik Jaafar NR, Abdul Rahman FN, Baharudin A, et al. Functional remission and employment among patients with schizophrenia in Malaysia. Compr Psychiatry. 2014;55(Suppl 1):S46–51.PubMedCrossRef
43.
go back to reference Charzyńska K, Kucharska K, Mortimer A. Does employment promote the process of recovery from schizophrenia? A review of the existing evidence. Int J Occup Med Environ Health. 2015;28(3):407–18.PubMedCrossRef Charzyńska K, Kucharska K, Mortimer A. Does employment promote the process of recovery from schizophrenia? A review of the existing evidence. Int J Occup Med Environ Health. 2015;28(3):407–18.PubMedCrossRef
44.
go back to reference Jordan G, Lutgens D, Joober R, Lepage M, Iyer SN, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014;75(6):e566–72.PubMedCrossRef Jordan G, Lutgens D, Joober R, Lepage M, Iyer SN, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014;75(6):e566–72.PubMedCrossRef
45.
go back to reference Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163(3):411–7.PubMedCrossRef Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163(3):411–7.PubMedCrossRef
46.
go back to reference Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107(2–3):232–7.PubMedCrossRef Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107(2–3):232–7.PubMedCrossRef
47.
go back to reference Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35(2):300–6.PubMedPubMedCentralCrossRef Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35(2):300–6.PubMedPubMedCentralCrossRef
48.
go back to reference Oorschot M, Lataster T, Thewissen V, Lardinois M, van Os J, Delespaul PAEG, et al. Symptomatic remission in psychosis and real-life functioning. Br J Psychiatry. 2012;201(3):215–20.PubMedCrossRef Oorschot M, Lataster T, Thewissen V, Lardinois M, van Os J, Delespaul PAEG, et al. Symptomatic remission in psychosis and real-life functioning. Br J Psychiatry. 2012;201(3):215–20.PubMedCrossRef
49.
go back to reference Feher EP, Mahurin RK, Doody RS, Cooke N, Sims J, Pirozzolo FJ. Establishing the limits of the mini-mental state. Examination of 'subtests'. Arch Neurol. 1992;49(1):87–92.PubMedCrossRef Feher EP, Mahurin RK, Doody RS, Cooke N, Sims J, Pirozzolo FJ. Establishing the limits of the mini-mental state. Examination of 'subtests'. Arch Neurol. 1992;49(1):87–92.PubMedCrossRef
50.
go back to reference Spencer RJ, Wendell CR, Giggey PP, Katzel LI, Lefkowitz DM, Siegel EL, et al. Psychometric limitations of the mini-mental state examination among nondemented older adults: an evaluation of neurocognitive and magnetic resonance imaging correlates. Exp Aging Res. 2013;39(4):382–97.PubMedCrossRef Spencer RJ, Wendell CR, Giggey PP, Katzel LI, Lefkowitz DM, Siegel EL, et al. Psychometric limitations of the mini-mental state examination among nondemented older adults: an evaluation of neurocognitive and magnetic resonance imaging correlates. Exp Aging Res. 2013;39(4):382–97.PubMedCrossRef
51.
go back to reference Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–13.PubMedCrossRef Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–13.PubMedCrossRef
52.
go back to reference Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2–3):283–97.PubMedCrossRef Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2–3):283–97.PubMedCrossRef
53.
go back to reference Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126(1–3):257–64.CrossRefPubMed Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126(1–3):257–64.CrossRefPubMed
55.
go back to reference Puig O, Penades R, Gasto C, Catalan R, Torres A, Salamero M. Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. Psychiatry Res. 2008;158(1):11–7.PubMedCrossRef Puig O, Penades R, Gasto C, Catalan R, Torres A, Salamero M. Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. Psychiatry Res. 2008;158(1):11–7.PubMedCrossRef
56.
go back to reference Vesterager L, Christensen TO, Olsen BB, Krarup G, Melau M, Forchhammer HB, et al. Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia. Schizophr Res. 2012;141(2–3):251–6.PubMedCrossRef Vesterager L, Christensen TO, Olsen BB, Krarup G, Melau M, Forchhammer HB, et al. Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia. Schizophr Res. 2012;141(2–3):251–6.PubMedCrossRef
57.
go back to reference Abdi H. Partial least squares (PLS) regression. In Lewis-Beck M, et al. (eds), Encyclopedia of social sciences research methods. Oak: Sage; 2003. p. 792-5. . Abdi H. Partial least squares (PLS) regression. In Lewis-Beck M, et al. (eds), Encyclopedia of social sciences research methods. Oak: Sage; 2003. p. 792-5. .
Metadata
Title
Symptomatic remission affects employment outcomes in schizophrenia patients
Authors
San-Ping Wang
Jung-Der Wang
Jer-Hao Chang
Bo-Jian Wu
Tso-Jen Wang
Hsiao-Ju Sun
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2020
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-020-02630-z

Other articles of this Issue 1/2020

BMC Psychiatry 1/2020 Go to the issue